Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.


Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 09 11 2020
accepted: 06 07 2021
pubmed: 11 8 2021
medline: 19 11 2021
entrez: 10 8 2021
Statut: ppublish

Résumé

The assessment of Programmed death-ligand 1 (PD-L1) expression has become a game changer in the treatment of patients with advanced non-small cell lung cancer (NSCLC). We aimed to investigate the ability of Radiomics applied to computed tomography (CT) in predicting PD-L1 expression in patients with advanced NSCLC. By applying texture analysis, we retrospectively analyzed 72 patients with advanced NSCLC. The datasets were randomly split into a training cohort (2/3) and a validation cohort (1/3). Forty radiomic features were extracted by manually drawing tumor volumes of interest (VOIs) on baseline contrast-enhanced CT. After selecting features on the training cohort, two predictive models were created using binary logistic regression, one for PD-L1 values ≥ 50% and the other for values between 1 and 49%. The two models were analyzed with ROC curves and tested in the validation cohort. The Radiomic Score (Rad-Score) for PD-L1 values ≥ 50%, which consisted of Skewness and Low Gray-Level Zone Emphasis (GLZLM_LGZE), presented a cut-off value of - 0.745 with an area under the curve (AUC) of 0.811 and 0.789 in the training and validation cohort, respectively. The Rad-Score for PD-L1 values between 1 and 49% consisted of Sphericity, Skewness, Conv_Q3 and Gray Level Non-Uniformity (GLZLM_GLNU), showing a cut-off value of 0.111 with AUC of 0.763 and 0.806 in the two population, respectively. Rad-Scores obtained from CT texture analysis could be useful for predicting PD-L1 expression and guiding the therapeutic choice in patients with advanced NSCLC.

Identifiants

pubmed: 34373989
doi: 10.1007/s11547-021-01399-9
pii: 10.1007/s11547-021-01399-9
pmc: PMC8558266
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1425-1433

Informations de copyright

© 2021. The Author(s).

Références

Cancer Imaging. 2013 Mar 26;13:140-9
pubmed: 23545171
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
Clin Radiol. 2017 Jun;72(6):443-450
pubmed: 28258739
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Eur J Radiol. 2019 Nov;120:108609
pubmed: 31606714
Sci Rep. 2016 Jan 29;6:20090
pubmed: 26822379
Acad Radiol. 2020 Feb;27(2):171-179
pubmed: 31147234
Radiographics. 2017 Sep-Oct;37(5):1483-1503
pubmed: 28898189
Clin Lung Cancer. 2015 Sep;16(5):385-90
pubmed: 25937270
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
J Thorac Oncol. 2017 Mar;12(3):458-466
pubmed: 27815126
Thorac Cancer. 2020 Apr;11(4):993-1004
pubmed: 32043309
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1137-1146
pubmed: 31728587
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Eur Radiol. 2018 Jul;28(7):2772-2778
pubmed: 29450713
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Xray Sci Technol. 2020;28(3):449-459
pubmed: 32176676
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
AJR Am J Roentgenol. 2015 Nov;205(5):1016-25
pubmed: 26496549
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Ann Oncol. 2019 Jun 1;30(6):998-1004
pubmed: 30895304

Auteurs

Stefano Bracci (S)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Miriam Dolciami (M)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Claudio Trobiani (C)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Antonella Izzo (A)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Angelina Pernazza (A)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Giulia D'Amati (G)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Lucia Manganaro (L)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.

Paolo Ricci (P)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. paolo.ricci@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH